---
schema_version: "secwatch.filing_event.v1"
accession: "0001161697-24-000140"
form_type: "8-K"
ticker: "KRMD"
cik: "0000704440"
company_name: "KORU Medical Systems, Inc."
filed_at: "2024-03-13T23:59:59+00:00"
generated_at: "2026-06-04T22:36:56.320969+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# KORU Medical reports Q4 rev $7.2M, FY net loss $13.7M; guides 2024 rev $31.2-32.2M

## Summary
- Q4 net revenues $7.2M (-2% YoY); gross margin improved to 60.3% (+470bps).
- Full year net loss $13.7M ($0.30/sh) includes $6M non-cash tax valuation allowance; Adjusted EBITDA ($6.0M) vs ($6.1M) prior year.
- Full year 2024 revenue guidance $31.2-32.2M (10-13% growth); gross margin 59-61%; cash flow breakeven in Q4 2024.
- Entered $10M credit facility with HSBC ($5M revolver + $5M term loan; undrawn); warrant for 76,104 shares at $2.12.
- EU notified body BSI recommended against continued certification; appeal filed; mgmt expects minimal revenue impact.

## SEC filing metadata
- accession: 0001161697-24-000140
- form_type: 8-K
- ticker: KRMD
- cik: 0000704440
- company_name: KORU Medical Systems, Inc.
- filed_at: 2024-03-13T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 1.01, 2.02, 2.03, 3.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/704440/000116169724000140/0001161697-24-000140-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/704440/000116169724000140/form_8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001161697-24-000140
- JSON: https://secwatch.observer/filing/0001161697-24-000140.json
- Plain text: https://secwatch.observer/filing/0001161697-24-000140.txt

## Key facts
- Earnings Releases
  KORU Medical Systems, Inc. reported the fourth quarter and year ended December 31, 2023 results: revenue $28.5 million, net income ($13.7) million, or ($0.30) per share.
  - Period: the fourth quarter and year ended December 31, 2023
  - Revenue: $28.5 million
  - Net income: ($13.7) million, or ($0.30) per share
  - Result: reported results
  source text: issued guidance for the full year 2024. Recent Highlights ● Fourth quarter 2023 net revenues of $7.2 million, a 2% decrease from the prior year; Full year 2023 net revenues of $28.5 million, a 2% increase over the prior year ● Full year 6.7% Core business growth (U.S. and International) driven by overall SCIg market growth, share gains and expansion in new
  evidence_url: https://www.sec.gov/Archives/edgar/data/704440/000116169724000140/0001161697-24-000140-index.htm
- Material Agreements
  KORU Medical Systems, Inc. entered into Loan and Security Agreement with HSBC Ventures USA Inc. valued at $5,000,000 (effective 2024-03-08).
  - Action: entry
  - Agreement: credit facility
  - Counterparty: HSBC Ventures USA Inc.
  - Value: $5,000,000
  - Effective: 2024-03-08
  source text: On March 8, 2024, KORU Medical Systems, Inc. (the “Company”) entered into a loan and security agreement (the “Loan and Security Agreement”), by and between the Company and HSBC Ventures USA Inc., as lender providing for a revolving credit facility in an aggregate principal amount not to exceed $5,000,000 (the “Revolver”) and a term loan facility in an aggregate principal amount not to exceed $5,000,000
  evidence_url: https://www.sec.gov/Archives/edgar/data/704440/000116169724000140/0001161697-24-000140-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.